Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder

Psychiatry Research

Volumn 215, Issue 2, 2014, Pages 355-361

  Ghasemi, Mehdi ^a,b,c,d   Kazemi, Mohammad H ^a,e   Yoosefi, Abolghasem ^a   Ghasemi, Abbas ^c   Paragomi, Pedram ^a   Amini, Homayoun ^a   Afzali, Mohammad H ^a,f  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d NeurExpand Brain Center   (United States)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^f UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Antidepressant; Electroconvulsive therapy (ECT); Hamilton Depression Rating Scale (HDRS); Ketamine; Major depressive disorder; NMDA receptor; NMDA receptor antagonist

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; KETAMINE; LAMOTRIGINE; LITHIUM SALT; OLANZAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; AGED; ANTIDEPRESSANT ACTIVITY; ARTICLE; BECK DEPRESSION INVENTORY; BLOOD PRESSURE MEASUREMENT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; ELECTROCONVULSIVE THERAPY; FEMALE; HAMILTON SCALE; HEART RATE; HOSPITAL PATIENT; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SCORING SYSTEM; SYSTOLIC BLOOD PRESSURE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; ELECTROCONVULSIVE THERAPY; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; KETAMINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84893715460     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.12.008     Document Type: Article

References (42)

1. Aan Het Rot M., Collins K.A., Murrough J.W., Perez A.M., Reich D.L., Charney D.S., Mathew S.J. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biological Psychiatry 2010, 67:139-145.
2. Aan Het Rot M., Zarate C.A., Charney D.S., Mathew S.J. Ketamine for depression: where do we go from here?. Biological Psychiatry 2012, 72:537-547.
3. Beck, A.T., 1961. Beck Depression Inventory. Center for Cognitive Therapy, Philadelphia PA.
4. Berman R.M., Krystal J.H., Charney D.S. Mechanism of action of antidepressants: monoamine hypotheses and beyond. Biology of Schizophrenia and Affective Disease 1996, American Psychiatric Press, Washington, DC. S.J. Watson (Ed.).
5. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000, 47:351-354.
6. Correll G.E., Futter G.E. Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Medicine 2006, 7:92-95.
7. Delgado P.L. Depression: the case for a monoamine deficiency. Journal of Clinical Psychiatry 2000, 61:7-11.
8. Denk M.C., Rewerts C., Holsboer F., Erhardt-Lehmann A., Turck C.W. Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. American Journal of Psychiatry 2011, 168:751-752.
9. Dierckx B., Heijnen W.T., van den Broek W.W., Birkenhager T.K. Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: a meta-analysis. Bipolar Disorder 2012, 14:146-150.
10. First M., Spitzer R., Gibbon M. Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition (SCIDI/P. Version 2.0). Biometric Research 1995, New York State Psychiatric Institute, New York, NY.
11. Ghasemi M. Ketamine as a promising drug for rapid treatment of major depression. Horizons in Neuroscience Research 2013, 10:75-102. Nova Science Publisher, New York, USA.
12. Ghasemi M., Schachter S.C. The NMDA receptor complex as a therapeutic target in epilepsy: a review. Epilepsy & Behavior 2011, 22:617-640.
13. Goforth H.W., Holsinger T. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. Journal of ECT 2007, 23:23-25.
14. Haghighi M., Salehi I., Erfani P., Jahangard L., Bajoghli H., Holsboer-Trachsler E., Brand S. Additional ECT increases BDNF-levels in patients suffering from major depressive disorders compared to patients treated with citalopram only. Journal of Psychiatry Research 2013, 47:908-915.
15. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 1960, 23:56-62.
16. Hoyer C., Kranaster L., Janke C., Sartorius A. Impact of the anesthetic agents ketamine, etomidate, thiopental, and propofol on seizure parameters and seizure quality in electroconvulsive therapy: a retrospective study. European Archives of Psychiatry and Clinical Neuroscience 2013, http://dx.doi.org/10.1007/s00406-013-0420-5.
17. Ibrahim L., Diazgranados N., Luckenbaugh D.A., Machado-Vieira R., Baumann J., Mallinger A.G., Zarate C.A. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2011, 35:1155-1159.
18. Irwin S.A., Iglewicz A., Nelesen R.A., Lo J.Y., Carr C.H., Romero S.D., Lloyd L.S. Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. Journal of Palliative Medicine 2013, 16:958-965.
19. Katz M.M., Tekell J.L., Bowden C.L., Brannan S., Houston J.P., Berman N., Frazer A. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology 2004, 29:566-579.
20. Kellner C.H., Greenberg R.M., Murrough J.W., Bryson E.O., Briggs M.C., Pasculli R.M. ECT in treatment-resistant depression. American Journal of Psychiatry 2012, 169:1238-1244.
21. Kudoh A., Takahira Y., Katagai H., Takazawa T. Small-dose ketamine improves the postoperative state of depressed patients. Anesthesia & Analgesia 2002, 95:114-118.
22. Lara D.R., Bisol L.W., Munari L.R. Antidepressant, mood stabilizing and procognitive effects of very low dose sublingual ketamine in refractory unipolar and bipolar depression. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum 2013, 16:2111-2117.
23. Liebrenz M., Borgeat A., Leisinger R., Stohler R. Intravenous ketamine therapy in a patient with a treatment-resistant major depression. Swiss Medical Weekly 2007, 137:234-236.
24. Machado-Vieira R., Salvadore G., Diazgranados N., Zarate C.A. Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacology & Therapeutics 2009, 123:143-150.
25. Machado-Vieira R., Yuan P., Brutsche N., Diazgranados N., Luckenbaugh D., Manji H.K., Zarate C.A. Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-d-aspartate antagonist. Journal of Clinical Psychiatry 2009, 70:1662-1666.
26. Mathew S.J., Shah A., Lapidus K., Clark C., Jarun N., Ostermeyer B., Murrough J.W. Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs 2012, 26:189-204.
27. Murrough J.W., Perez A.M., Mathew S.J., Charney D.S. A case of sustained remission following an acute course of ketamine in treatment-resistant depression. Journal of Clinical Psychiatry 2011, 72:414-415.
28. Nobler M.S., Sackeim H.A., Moeller J.R., Prudic J., Petkova E., Waternaux C. Quantifying the speed of symptomatic improvement with electroconvulsive therapy: comparison of alternative statistical methods. Convulsive Therapy 1997, 13:208-221.
29. Okamoto N., Nakai T., Sakamoto K., Nagafusa Y., Higuchi T., Nishikawa T. Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia. Journal of ECT 2010, 26:223-227.
30. Ostroff R., Gonzales M., Sanacora G. Antidepressant effect of ketamine during ECT. American Journal of Psychiatry 2005, 162:1385-1386.
31. Papolos D.F., Teicher M.H., Faedda G.L., Murphy P., Mattis S. Clinical experience using intranasal ketamine in the treatment of pediatric bipolar disorder/fear of harm phenotype. Journal of Affective Disorders 2013, 147:431-436.
32. Patel A. The cost of mood disorders. Psychiatry 2008, 8:76-80.
33. Phelps L.E., Brutsche N., Moral J.R., Luckenbaugh D.A., Manji H.K., Zarate C.A. Family history of alcohol dependence and initial antidepressant response to an N-methyl-d-aspartate antagonist. Biological Psychiatry 2009, 65:181-184.
34. Prabhakar H., Bindra A., Singh G.P., Kalaivani M. Propofol versus thiopental sodium for the treatment of refractory status epilepticus (Review). Evidence-Based Child Health: A Cochrane Review Journal 2013, 8:1488-1508.
35. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biological Psychiatry 2009, 66:522-526.
36. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., Rosenbaum J.F., Sackeim H.A., Kupfer D.J., Luther J., Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 2006, 163:1905-1917.
37. Tiller J.W., Ingram N. Seizure threshold determination for electroconvulsive therapy: stimulus dose titration versus age-based estimations. The Australian and New Zealand Journal of Psychiatry 2006, 40:188-192.
38. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., Norquist G., Howland R.H., Lebowitz B., McGrath P.J., Shores-Wilson K., Biggs M.M., Balasubramani G.K., Fava M. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 2006, 163:28-40.
39. Trullas R., Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. European Journal of Pharmacology 1990, 185:1-10.
40. Wang X., Chen Y., Zhou X., Liu F., Zhang T., Zhang C. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. Journal of ECT 2012, 28:128-132.
41. Zanicotti C.G., Perez D., Glue P. Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. Journal of Palliative Medicine 2012, 15:400-403.
42. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 2006, 63:856-864.